Margarita V. Teleshova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Margarita V. Teleshova has a total of 184 co-authors. Here are the top co-authors by number of shared publications:
- Denis Y. Kachanov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
26 shared publications - Tatyana V. Shamanskaya
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of the Russian Federation
19 shared publications - Nikolay Sergeevich Grachev
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Health of the Russian Federation
13 shared publications - Dmitriy G. Akhaladze
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Health of the Russian Federation
11 shared publications - Dmitry M. Konovalov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
11 shared publications - Nikolay N. Merkulov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
10 shared publications
Latest Publications
- Open Access
- 19 August 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (3) , 34-44
Myoepithelial carcinoma of bones and soft tissues in children: a single-center experience
Introduction. Myoepithelial сarcinoma (MC) is a rare and highly malignant neoplasm. Primary soft tissue involvement predominates in pediatrics (MCST), while MC of bones has been described in isolated cases. The rarity of MC combined with its polymorphic phenotype significantly challenge diagnosis and determine the absence of standardized treatment approaches. Aim: to analyze the specifics of diagnosis and treatment of children with MC at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Health of the Russian Federation. Material and methods. The study included 7 patients aged 1.3 to 14.2 years who were diagnosed with MC and registered between 2017 and 2024. Results and discussion. MC of soft tissue was diagnosed in 6/7 cases and MC of bones in 1/7. Five out of seven cases were localized, while 2/7 cases presented with distant metastases. In 3 cases a deletion of the SMARCB1 gene was identified, and in 1 case deletion of the EWSR1 gene was detected. Surgical resection proved to be the cornerstone of the treatment program for patients with MC (R0 – n = 3; R1 – n = 3; R2 – n = 1). 5 patients underwent external beam radiation therapy. In 4 cases of localized MC, courses of chemotherapy (ICpE) were administered as an adjuvant. In 1 case courses of ICpE and IVE were given perioperatively. In the first case of metastatic MCST courses of ICpE/IVE were also administered; and in the second case a combination of AP + vinorelbine was used. Follow-up outcomes: 4/7 patients are alive with 3/4 alive without events. Conclusion. The results of our study mostly align with international experience and emphasize the significance of local control, as well as the leading role of a multidisciplinary approach and multicenter data sharing in improving the diagnostic and therapeutic outcomes for patients with MC.
- 19 August 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (3) , 34-44
Open AccessMyoepithelial carcinoma of bones and soft tissues in children: a single-center experience
Introduction. Myoepithelial сarcinoma (MC) is a rare and highly malignant neoplasm. Primary soft tissue involvement predominates in pediatrics (MCST), while MC of bones has been described in isolated cases. The rarity of MC combined with its polymorphic phenotype significantly challenge diagnosis and determine the absence of standardized treatment approaches. Aim: to analyze the specifics of diagnosis and treatment of children with MC at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Health of the Russian Federation. Material and methods. The study included 7 patients aged 1.3 to 14.2 years who were diagnosed with MC and registered between 2017 and 2024. Results and discussion. MC of soft tissue was diagnosed in 6/7 cases and MC of bones in 1/7. Five out of seven cases were localized, while 2/7 cases presented with distant metastases. In 3 cases a deletion of the SMARCB1 gene was identified, and in 1 case deletion of the EWSR1 gene was detected. Surgical resection proved to be the cornerstone of the treatment program for patients with MC (R0 – n = 3; R1 – n = 3; R2 – n = 1). 5 patients underwent external beam radiation therapy. In 4 cases of localized MC, courses of chemotherapy (ICpE) were administered as an adjuvant. In 1 case courses of ICpE and IVE were given perioperatively. In the first case of metastatic MCST courses of ICpE/IVE were also administered; and in the second case a combination of AP + vinorelbine was used. Follow-up outcomes: 4/7 patients are alive with 3/4 alive without events. Conclusion. The results of our study mostly align with international experience and emphasize the significance of local control, as well as the leading role of a multidisciplinary approach and multicenter data sharing in improving the diagnostic and therapeutic outcomes for patients with MC.
- 3 April 2026
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 13 (1)
Juxtaglomerular cell tumor of the kidney in an 11-year-old child: case report
Background. The juxtaglomerular cell tumor (JCT) of the kidney, or reninoma, is a rare benign renal neoplasm that occurs exceptionally rarely in pediatric patients. In contrast to other renal tumors, JCT pathogenesis is driven by renin-angiotensin system activation, clinically manifesting as refractory hypertension due to excessive tumor-derived renin secretion. We present a clinical case of an 11-year-old patient with JCT. Materials and methods . From January 2012 to January 2025 in the Pathology Department of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology only one case of JCT was identified. Results. An 11-year-old girl had headaches and developed arterial hypertension (blood pressure 170/90 mmHg) during 3 months. Abdominal ultrasound revealed a tumor in the left kidney. Further evaluation at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology showed contrast-enhanced abdominal computed tomography demonstrated a solid, heterogeneous mass (3.2 × 2.9 × 3.0 cm, V = 14.5 cm3) in the midsegment of the left kidney. There were no metastatic lung lesions on contrast-enhanced chest computed tomography. According to the clinical-radiological findings, patient's age (11 years), and tumor characteristics (size < 200 cm3), nephron-sparing surgery was performed. The patient underwent initial laparoscopic left kidney resection with lymph node sampling. Histopathological examination confirmed the diagnosis of JCT and radical tumor resection. Arterial hypertension was relieved in the postoperative period. Conclusions. The diagnosis and management of JCT require a multidisciplinary approach integrating clinical presentation, laboratory parameters, and expertise from pediatric oncologists, radiologists, surgeons, and pathologists. Given the tumor's typically small dimensions and benign biological behavior nephron-sparing surgery should be discussed with curative intent.
- 3 April 2026
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 13 (1)
Juxtaglomerular cell tumor of the kidney in an 11-year-old child: case report
Background. The juxtaglomerular cell tumor (JCT) of the kidney, or reninoma, is a rare benign renal neoplasm that occurs exceptionally rarely in pediatric patients. In contrast to other renal tumors, JCT pathogenesis is driven by renin-angiotensin system activation, clinically manifesting as refractory hypertension due to excessive tumor-derived renin secretion. We present a clinical case of an 11-year-old patient with JCT. Materials and methods . From January 2012 to January 2025 in the Pathology Department of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology only one case of JCT was identified. Results. An 11-year-old girl had headaches and developed arterial hypertension (blood pressure 170/90 mmHg) during 3 months. Abdominal ultrasound revealed a tumor in the left kidney. Further evaluation at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology showed contrast-enhanced abdominal computed tomography demonstrated a solid, heterogeneous mass (3.2 × 2.9 × 3.0 cm, V = 14.5 cm3) in the midsegment of the left kidney. There were no metastatic lung lesions on contrast-enhanced chest computed tomography. According to the clinical-radiological findings, patient's age (11 years), and tumor characteristics (size < 200 cm3), nephron-sparing surgery was performed. The patient underwent initial laparoscopic left kidney resection with lymph node sampling. Histopathological examination confirmed the diagnosis of JCT and radical tumor resection. Arterial hypertension was relieved in the postoperative period. Conclusions. The diagnosis and management of JCT require a multidisciplinary approach integrating clinical presentation, laboratory parameters, and expertise from pediatric oncologists, radiologists, surgeons, and pathologists. Given the tumor's typically small dimensions and benign biological behavior nephron-sparing surgery should be discussed with curative intent.
- Open Access
- 13 December 2025
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (3) , 61-69
Eosinophilia and allergic reactions during immunotherapy with dinutuximab beta in patients with neuroblastoma
Introduction. Over the past two decades, immunotherapy has become the standard of treatment for some solid malignancies in children including neuroblastoma (NB). It is a relatively safe treatment modality if appropriate supportive care is provided. However, like other treatments, immunotherapy can result in a unique toxicity profile that requires timely interpretation and appropriate management. One of the described side effects is eosinophilia that in some cases can be accompanied by adverse events affecting various organs and systems. Mechanisms of injury, critical target organs, and approaches to management are still understudied. Aim – to study the relationship between increased peripheral blood eosinophil counts and adverse events including clinical symptoms of acute tonsillitis developing during immunotherapy with dinutuximab beta in patients with NB. Being a retrospective analysis, this study did not require approval from the local Ethics Committee. Materials and methods. We retrospectively analyzed the medical history and clinical and laboratory data of 40 patients with NB who had undergone immunotherapy with dinutuximab beta as first- or second-line treatment at the Dmitry Rogachev National Medical Research Center from 2019 to 2023. Results. Eosinophilia was seen to develop between immunotherapy cycles and was accompanied by skin reactions in 47.5% of cases (in 19/40 patients) and by itchiness (14/40), bronchial obstruction syndrome (14/40) or acute tonsillitis (14/40) – in 35% of cases. From сycle to cycle, there was a tendency towards a decrease in maximum absolute eosinophil count as well as in the incidence of itchiness. At the same time, skin reactions and acute tonsillitis developed almost as frequently in the following cycles. A comparison of clinical symptoms with laboratory data revealed that eosinophilia was significantly correlated only with acute tonsillitis (p 0.05). In this study, we investigated potential causes of this condition. We reported a clinical case of acute tonsillitis that had developed during immunotherapy with dinutuximab beta confirming the hypothesis about the potential infiltration of the tonsils by eosinophils. Conclusions. One of the side effects of immunotherapy with dinutuximab beta in NB patients is non-infectious tonsillitis which can be confirmed by a histological analysis showing morphological features of eosinophilic infiltration of the palatine tonsils. A differential diagnosis between this condition and infections as well as careful monitoring of patients treated with dinutuximab beta is required for timely identification and correct interpretation of adverse reactions.
- 13 December 2025
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (3) , 61-69
Open AccessEosinophilia and allergic reactions during immunotherapy with dinutuximab beta in patients with neuroblastoma
Introduction. Over the past two decades, immunotherapy has become the standard of treatment for some solid malignancies in children including neuroblastoma (NB). It is a relatively safe treatment modality if appropriate supportive care is provided. However, like other treatments, immunotherapy can result in a unique toxicity profile that requires timely interpretation and appropriate management. One of the described side effects is eosinophilia that in some cases can be accompanied by adverse events affecting various organs and systems. Mechanisms of injury, critical target organs, and approaches to management are still understudied. Aim – to study the relationship between increased peripheral blood eosinophil counts and adverse events including clinical symptoms of acute tonsillitis developing during immunotherapy with dinutuximab beta in patients with NB. Being a retrospective analysis, this study did not require approval from the local Ethics Committee. Materials and methods. We retrospectively analyzed the medical history and clinical and laboratory data of 40 patients with NB who had undergone immunotherapy with dinutuximab beta as first- or second-line treatment at the Dmitry Rogachev National Medical Research Center from 2019 to 2023. Results. Eosinophilia was seen to develop between immunotherapy cycles and was accompanied by skin reactions in 47.5% of cases (in 19/40 patients) and by itchiness (14/40), bronchial obstruction syndrome (14/40) or acute tonsillitis (14/40) – in 35% of cases. From сycle to cycle, there was a tendency towards a decrease in maximum absolute eosinophil count as well as in the incidence of itchiness. At the same time, skin reactions and acute tonsillitis developed almost as frequently in the following cycles. A comparison of clinical symptoms with laboratory data revealed that eosinophilia was significantly correlated only with acute tonsillitis (p 0.05). In this study, we investigated potential causes of this condition. We reported a clinical case of acute tonsillitis that had developed during immunotherapy with dinutuximab beta confirming the hypothesis about the potential infiltration of the tonsils by eosinophils. Conclusions. One of the side effects of immunotherapy with dinutuximab beta in NB patients is non-infectious tonsillitis which can be confirmed by a histological analysis showing morphological features of eosinophilic infiltration of the palatine tonsils. A differential diagnosis between this condition and infections as well as careful monitoring of patients treated with dinutuximab beta is required for timely identification and correct interpretation of adverse reactions.
- Open Access
- 26 October 2025
- Published by Central Research Institute of Radiation Diagnostics in Radiology - Practice
- No. 5,p. 11-19
Radiological Diagnostics of Totally Necrotic Nephroblastomas
Aim. To determine the radiological semiotics of totally necrotic nephroblastoma. Materialsand Methods. Thestudyincluded 12 patientswithtotallynecroticnephroblastoma who underwent contrast-enhanced MSCT after specific therapy. Fractional enhancement contrast values were measured at a random tumor site. Radiological diagnostic data and pathological anatomy were compared. Results. The values of the contrast enhancement fraction were determined, which amounted to 0.026 (2.6 %) for the arterial phase and 0.121 (12.1 %) for the venous phase. Conclusion. Totally necrotic nephroblastoma, both histologically and radiologically, have a homologous structure, do not significantly accumulate contrast agent, may have a capsule and septa.
- 26 October 2025
- Published by Central Research Institute of Radiation Diagnostics in Radiology - Practice
- No. 5,p. 11-19
Open AccessRadiological Diagnostics of Totally Necrotic Nephroblastomas
Aim. To determine the radiological semiotics of totally necrotic nephroblastoma. Materialsand Methods. Thestudyincluded 12 patientswithtotallynecroticnephroblastoma who underwent contrast-enhanced MSCT after specific therapy. Fractional enhancement contrast values were measured at a random tumor site. Radiological diagnostic data and pathological anatomy were compared. Results. The values of the contrast enhancement fraction were determined, which amounted to 0.026 (2.6 %) for the arterial phase and 0.121 (12.1 %) for the venous phase. Conclusion. Totally necrotic nephroblastoma, both histologically and radiologically, have a homologous structure, do not significantly accumulate contrast agent, may have a capsule and septa.
- Open Access
- 8 September 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (3) , 68-79
Metanephric tumors in children and adolescents: clinical, morphological and molecular genetic characteristics
Metanephric tumors (MTs) are a group of rare childhood kidney tumors consisting of epithelial and/or stromal cellular elements and characterized by a variety of histopathological features. MTs include metanephric adenoma (MA), metanephric adenofibroma (MAF), and metanephric stromal tumor (MST). This study aimed to retrospectively analyse clinical and molecular genetic characteristics of MTs, verified at the Pathology Department of the Dmitry Rogachev NMRCPHOI of Ministry of Healthcare of the Russian Federation. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. We performed a retrospective analysis of data on patients with MTs histologically confirmed between February 2015 and February 2024 (109 months). During this period, a total of 26 cases (patients aged 0–18 years) of histologically confirmed MA, MAF, and MST had been documented at the Pathology Department of the D. Rogachev Center. Out of these 26 cases, 16 patients with known clinical data were included in our analysis. The median age at diagnosis was 3.5 years (range: 0.4–15.2 years). The boys:girls ratio was 1:1. The analysis of primary complaints showed that the majority of patients (n = 8; 50%) were asymptomatic and their kidney masses were detected by chance. The rest of the patients presented with pain syndrome (n = 3; 19%), gross hematuria (n = 2; 13%), intoxication syndrome (n = 1; 6%), polycythemia (n = 1; 6%), an increased abdominal circumference (n = 1; 6%). Primary surgery was performed in 6 (37%) patients: partial nephrectomy (n = 4), total nephrectomy (n = 1), and a core needle biopsy of the mass followed by partial nephrectomy (n = 1). Ten patients (63%) underwent preoperative multiagent chemotherapy. The analysis of the extent of surgical treatment of all patients included in the analysis (n = 16) showed that total nephrectomy was performed in 9 cases, and partial nephrectomy – in 7 cases. R0 resection was achieved in 15 cases, R1 resection – in 1 case. The distribution by histological variants was as follows: MA – 10 (63%) patients, MST – 3 (19%) patients, MAF – 1 (6%) patient, MA in combination with clear cell papillary renal cell carcinoma – 1 (6%) patient, MAF in combination with papillary renal cell carcinoma – 1 (6%) patient. Sixteen patients underwent molecular genetic testing: a somatic V600E mutation in the BRAF gene was detected in 10/16 (62.5%) patients. Currently, all patients are alive, and no relapses of the disease have been observed. MTs are a group of rare kidney tumors in children, characterized by a variety of histological patterns, which creates difficulties in differential diagnosis with other kidney tumors, such as renal cell carcinoma and nephroblastoma. Molecular genetic testing aimed at identifying mutations in the BRAF gene can help in establishing the correct morphological diagnosis.
- 8 September 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (3) , 68-79
Open AccessMetanephric tumors in children and adolescents: clinical, morphological and molecular genetic characteristics
Metanephric tumors (MTs) are a group of rare childhood kidney tumors consisting of epithelial and/or stromal cellular elements and characterized by a variety of histopathological features. MTs include metanephric adenoma (MA), metanephric adenofibroma (MAF), and metanephric stromal tumor (MST). This study aimed to retrospectively analyse clinical and molecular genetic characteristics of MTs, verified at the Pathology Department of the Dmitry Rogachev NMRCPHOI of Ministry of Healthcare of the Russian Federation. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. We performed a retrospective analysis of data on patients with MTs histologically confirmed between February 2015 and February 2024 (109 months). During this period, a total of 26 cases (patients aged 0–18 years) of histologically confirmed MA, MAF, and MST had been documented at the Pathology Department of the D. Rogachev Center. Out of these 26 cases, 16 patients with known clinical data were included in our analysis. The median age at diagnosis was 3.5 years (range: 0.4–15.2 years). The boys:girls ratio was 1:1. The analysis of primary complaints showed that the majority of patients (n = 8; 50%) were asymptomatic and their kidney masses were detected by chance. The rest of the patients presented with pain syndrome (n = 3; 19%), gross hematuria (n = 2; 13%), intoxication syndrome (n = 1; 6%), polycythemia (n = 1; 6%), an increased abdominal circumference (n = 1; 6%). Primary surgery was performed in 6 (37%) patients: partial nephrectomy (n = 4), total nephrectomy (n = 1), and a core needle biopsy of the mass followed by partial nephrectomy (n = 1). Ten patients (63%) underwent preoperative multiagent chemotherapy. The analysis of the extent of surgical treatment of all patients included in the analysis (n = 16) showed that total nephrectomy was performed in 9 cases, and partial nephrectomy – in 7 cases. R0 resection was achieved in 15 cases, R1 resection – in 1 case. The distribution by histological variants was as follows: MA – 10 (63%) patients, MST – 3 (19%) patients, MAF – 1 (6%) patient, MA in combination with clear cell papillary renal cell carcinoma – 1 (6%) patient, MAF in combination with papillary renal cell carcinoma – 1 (6%) patient. Sixteen patients underwent molecular genetic testing: a somatic V600E mutation in the BRAF gene was detected in 10/16 (62.5%) patients. Currently, all patients are alive, and no relapses of the disease have been observed. MTs are a group of rare kidney tumors in children, characterized by a variety of histological patterns, which creates difficulties in differential diagnosis with other kidney tumors, such as renal cell carcinoma and nephroblastoma. Molecular genetic testing aimed at identifying mutations in the BRAF gene can help in establishing the correct morphological diagnosis.
- Open Access
- 8 September 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (3) , 143-157
Relapses of congenital mesoblastic nephroma: description of three clinical cases and literature review
Congenital mesoblastic nephroma (CMN) is a rare renal tumor of young children with intermediate biological behavior, accounting for 3.5-4% of all renal tumors in children. СMN is characterized by a favorable prognosis in case of radical surgical treatment. Relapses of CMN are considered to be quite a rare occurrence (4% of all cases), however, both local and metastatic relapses are possible. There are no fully standardized treatment approaches for patients with relapsed CMN. In our study, we performed a retrospective analysis of patients (n = 3) with a verified relapse of CMN who had received treatment at the D. Rogachev NMRCPHOI between 2012 to 2022 (132 months). At relapse, all the patients underwent at least one part of treatment at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. The diagnosis of CMN was established at the Pathology Department of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation, based on a histological examination. The patients with the cellular histological subtype of CMN underwent fluorescent in situ hybridization testing for ETV6 gene rearrangements. The demographic characteristics, clinical data, the extent of initial treatment and relapse therapy were assessed. Here, we describe three clinical cases of relapse in patients with CMN. The median age at initial diagnosis was 0.8 months (range 0.7–1.4). Our analysis of the extent of primary surgical treatment, including nephrectomy, in all cases revealed the following factors associated with a higher risk of relapse: preoperative tumor rupture – 1, intraoperative tumor rupture – 1, inability to confirm tumor-free margins – 1. The distribution of histological subtypes was as following: classical CMN (n = 1), cellular CMN (n = 1), and mixed CMN (n = 1). One patient had local stage II and 2 patients had local stage III. The median time from diagnosis to disease relapse was 0.8 months (range 2.3–4.3). One patient with mixed CMN died 10.6 months after diagnosis from complications of intensive therapy carried out for extremely aggressive relapse. Two patients are alive after repeated surgical treatment (R1 resection) and adjuvant therapy with actinomycin D and vincristine (AV regimen) for 27 weeks in one case, and neoadjuvant therapy (AV regimen for 4 weeks), delayed surgery (R0 resection), and adjuvant therapy (AV regimen for 4 weeks) in the other case. These patients were followed up for 92.2 and 21.3 months, respectively. By acknowledging the possibility of recurrent CMN, it seems important to provide multidisciplinary clinical care to young children with renal tumors involving a detailed planning of surgical procedures, radical surgeries in accordance with practice guidelines and standards in surgical oncology, and careful follow-up, especially during the first year after surgery. The patients' parents gave consent to the use of their children's data, including photographs, for research purposes and in publications.
- 8 September 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (3) , 143-157
Open AccessRelapses of congenital mesoblastic nephroma: description of three clinical cases and literature review
Congenital mesoblastic nephroma (CMN) is a rare renal tumor of young children with intermediate biological behavior, accounting for 3.5-4% of all renal tumors in children. СMN is characterized by a favorable prognosis in case of radical surgical treatment. Relapses of CMN are considered to be quite a rare occurrence (4% of all cases), however, both local and metastatic relapses are possible. There are no fully standardized treatment approaches for patients with relapsed CMN. In our study, we performed a retrospective analysis of patients (n = 3) with a verified relapse of CMN who had received treatment at the D. Rogachev NMRCPHOI between 2012 to 2022 (132 months). At relapse, all the patients underwent at least one part of treatment at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. The diagnosis of CMN was established at the Pathology Department of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation, based on a histological examination. The patients with the cellular histological subtype of CMN underwent fluorescent in situ hybridization testing for ETV6 gene rearrangements. The demographic characteristics, clinical data, the extent of initial treatment and relapse therapy were assessed. Here, we describe three clinical cases of relapse in patients with CMN. The median age at initial diagnosis was 0.8 months (range 0.7–1.4). Our analysis of the extent of primary surgical treatment, including nephrectomy, in all cases revealed the following factors associated with a higher risk of relapse: preoperative tumor rupture – 1, intraoperative tumor rupture – 1, inability to confirm tumor-free margins – 1. The distribution of histological subtypes was as following: classical CMN (n = 1), cellular CMN (n = 1), and mixed CMN (n = 1). One patient had local stage II and 2 patients had local stage III. The median time from diagnosis to disease relapse was 0.8 months (range 2.3–4.3). One patient with mixed CMN died 10.6 months after diagnosis from complications of intensive therapy carried out for extremely aggressive relapse. Two patients are alive after repeated surgical treatment (R1 resection) and adjuvant therapy with actinomycin D and vincristine (AV regimen) for 27 weeks in one case, and neoadjuvant therapy (AV regimen for 4 weeks), delayed surgery (R0 resection), and adjuvant therapy (AV regimen for 4 weeks) in the other case. These patients were followed up for 92.2 and 21.3 months, respectively. By acknowledging the possibility of recurrent CMN, it seems important to provide multidisciplinary clinical care to young children with renal tumors involving a detailed planning of surgical procedures, radical surgeries in accordance with practice guidelines and standards in surgical oncology, and careful follow-up, especially during the first year after surgery. The patients' parents gave consent to the use of their children's data, including photographs, for research purposes and in publications.
- Open Access
- 20 December 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (4) , 37-51
An analysis of the effectiveness of differential diagnosis and surgical treatment of neck soft-tissue sarcomas in children
We conducted a retrospective sample study with prospective collection of follow-up data. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. In the time period from January 2013 to August 2020 (92 months), 126 patients with head and neck soft-tissue sarcomas (STS) received treatment at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. We included 25 patients who had undergone surgery for neck STS and divided them into 4 groups (rhabdomyosarcoma (RMS), non-RMS-like STS, RMS-like STS, IRS-IV STS – with distant metastasis at baseline). The median age at the time of correct diagnosis was 2.6 (0.5; 5.0). The median time from symptom onset to the verification of the correct pathomorphological diagnosis was 3.2 (1.6; 4.9) months. We discovered a significant number (13/25, 52%) of cases of biopsy that was performed improperly (excessive/non-diagnostic biopsy, fine-needle aspiration biopsy) at a general inpatient facility. The correct pathomorphological diagnosis was clinically and statistically much more often made at a reference center (20/25, 80%; p = 0.003). Moreover, more than half of pathomorphological diagnoses (8/13, 62%) made at a general inpatient facility were later changed at a reference center. Radical resection was achieved in 17/20 (85%) survivors. In 3/20 (15%) cases, a repeat surgery was not needed because of the patients' complete response to protocol-based treatment. Radiotherapy was carried out in 11/25 (44%) cases. Protocol-based treatment was completed in 19/25 (76%) patients, 18/25 (72%) patients achieved complete response, 2/25 (8%) patients were considered incurable, and 4/25 (16%) children died before the completion of therapy. Post-operative complications of varying severity were observed in 10/25 (40%) cases and were dependent on the degree of STS extension and the severity of the condition of the patients undergoing intensive protocol-based treatment. The median time of patient observation since diagnosis verification was 33.2 (15.6; 74.2) months. The five-year overall survival (OS) was 76.3% (95% confidence interval (CI) 51.8; 89.5), the five-year event-free survival without local disease progression – 73.9% (95% CI 41.8–90.1). Even though there weren't many patients with IRS-IV in our study (4/25, 16%), their exclusion from the analysis resulted in a higher 5-year OS rate: 88.2% (95% CI 60.2; 96.9). This study revealed significant problems in the differential diagnosis of neck STSs in children. In most patients receiving optimal protocol-based treatment, neck tumors can be radically removed at a specialized healthcare facility without mutilating surgery, which results in high 5-year OS and event-free survival rates in patients without distant metastasis. Our findings require further investigation in a larger sample of patients.
- 20 December 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (4) , 37-51
Open AccessAn analysis of the effectiveness of differential diagnosis and surgical treatment of neck soft-tissue sarcomas in children
We conducted a retrospective sample study with prospective collection of follow-up data. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. In the time period from January 2013 to August 2020 (92 months), 126 patients with head and neck soft-tissue sarcomas (STS) received treatment at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. We included 25 patients who had undergone surgery for neck STS and divided them into 4 groups (rhabdomyosarcoma (RMS), non-RMS-like STS, RMS-like STS, IRS-IV STS – with distant metastasis at baseline). The median age at the time of correct diagnosis was 2.6 (0.5; 5.0). The median time from symptom onset to the verification of the correct pathomorphological diagnosis was 3.2 (1.6; 4.9) months. We discovered a significant number (13/25, 52%) of cases of biopsy that was performed improperly (excessive/non-diagnostic biopsy, fine-needle aspiration biopsy) at a general inpatient facility. The correct pathomorphological diagnosis was clinically and statistically much more often made at a reference center (20/25, 80%; p = 0.003). Moreover, more than half of pathomorphological diagnoses (8/13, 62%) made at a general inpatient facility were later changed at a reference center. Radical resection was achieved in 17/20 (85%) survivors. In 3/20 (15%) cases, a repeat surgery was not needed because of the patients' complete response to protocol-based treatment. Radiotherapy was carried out in 11/25 (44%) cases. Protocol-based treatment was completed in 19/25 (76%) patients, 18/25 (72%) patients achieved complete response, 2/25 (8%) patients were considered incurable, and 4/25 (16%) children died before the completion of therapy. Post-operative complications of varying severity were observed in 10/25 (40%) cases and were dependent on the degree of STS extension and the severity of the condition of the patients undergoing intensive protocol-based treatment. The median time of patient observation since diagnosis verification was 33.2 (15.6; 74.2) months. The five-year overall survival (OS) was 76.3% (95% confidence interval (CI) 51.8; 89.5), the five-year event-free survival without local disease progression – 73.9% (95% CI 41.8–90.1). Even though there weren't many patients with IRS-IV in our study (4/25, 16%), their exclusion from the analysis resulted in a higher 5-year OS rate: 88.2% (95% CI 60.2; 96.9). This study revealed significant problems in the differential diagnosis of neck STSs in children. In most patients receiving optimal protocol-based treatment, neck tumors can be radically removed at a specialized healthcare facility without mutilating surgery, which results in high 5-year OS and event-free survival rates in patients without distant metastasis. Our findings require further investigation in a larger sample of patients.
- Open Access
- 20 December 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (4) , 23-36-36
Angiosarcoma in children: the experience of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology and literature review
Angiosarcoma is a rare and highly malignant endothelial tumor, which occurs mainly in adults and is extremely rare in children and adolescents. The German guidelines for the treatment of soft tissue sarcomas provided by the Cooperative Weichteilsarkom Studiengruppe in 2012 included a separate therapeutic regimen for pediatric angiosarcoma consisting of a combination of vincristine/doxorubicin/cyclophosphamide (VDC) and paclitaxel. The aim of this article was to describe the epidemiological, clinical, and morphological characteristics of angiosarcoma, to review treatment approaches, and to present the experience of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation in the treatment of children with angiosarcoma. Our study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. The study included 5 patients diagnosed with angiosarcoma who had received treatment between 2012 and 2022. The patients’ parents gave consent to the use of their child's data, including photographs, for research purposes and in publications. Data on the patients’ age, gender, tumor location and extension, performed treatment and outcomes of the disease were analyzed. The male:female ratio was 0.66:1 and the median age was 5.2 years. Tumors were located in the soft tissues (n = 3) and in the bones (n = 2). In all the cases, invasion of the surrounding tissues was observed. There were no distant metastases at the time of diagnosis. Two (40%) patients underwent primary resection (R1) and 3 (60%) patients had tumor biopsy. Four patients received therapy according to the German guidelines for the treatment of angiosarcoma (VDC/paclitaxel courses), and 1 patient received treatment according to the guidelines for the management of non-rhabdomyosarcoma soft-tissue sarcomas (courses with vincristine, ifosfamide, doxorubicin/ vincristine, ifosfamide, actinomycin D). Objective response to treatment was achieved in 3 (60%) cases. Local control treatment of these 3 patients consisted of radiation therapy with a total dose of 50.4 Gy after R1 resection in 2 cases and biopsy in 1 case. After a median follow-up of 32 months, 2 patients who had received VDC/paclitaxel were alive without events (with complete and partial response), 3 patients died of progressive disease. Our data confirm the aggressive behavior of angiosarcoma in children. Protocol therapy that includes multiagent chemotherapy based on paclitaxel and doxorubicin along with local control treatment makes it possible to achieve a long-term control of the disease in some patients. However, further research on molecular and genetic characteristics of angiosarcoma is required to find potential novel targets for molecular targeted therapy. Further studies investigating the effectiveness of checkpoint inhibitors in angiosarcoma are also needed.
- 20 December 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (4) , 23-36-36
Open AccessAngiosarcoma in children: the experience of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology and literature review
Angiosarcoma is a rare and highly malignant endothelial tumor, which occurs mainly in adults and is extremely rare in children and adolescents. The German guidelines for the treatment of soft tissue sarcomas provided by the Cooperative Weichteilsarkom Studiengruppe in 2012 included a separate therapeutic regimen for pediatric angiosarcoma consisting of a combination of vincristine/doxorubicin/cyclophosphamide (VDC) and paclitaxel. The aim of this article was to describe the epidemiological, clinical, and morphological characteristics of angiosarcoma, to review treatment approaches, and to present the experience of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation in the treatment of children with angiosarcoma. Our study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. The study included 5 patients diagnosed with angiosarcoma who had received treatment between 2012 and 2022. The patients’ parents gave consent to the use of their child's data, including photographs, for research purposes and in publications. Data on the patients’ age, gender, tumor location and extension, performed treatment and outcomes of the disease were analyzed. The male:female ratio was 0.66:1 and the median age was 5.2 years. Tumors were located in the soft tissues (n = 3) and in the bones (n = 2). In all the cases, invasion of the surrounding tissues was observed. There were no distant metastases at the time of diagnosis. Two (40%) patients underwent primary resection (R1) and 3 (60%) patients had tumor biopsy. Four patients received therapy according to the German guidelines for the treatment of angiosarcoma (VDC/paclitaxel courses), and 1 patient received treatment according to the guidelines for the management of non-rhabdomyosarcoma soft-tissue sarcomas (courses with vincristine, ifosfamide, doxorubicin/ vincristine, ifosfamide, actinomycin D). Objective response to treatment was achieved in 3 (60%) cases. Local control treatment of these 3 patients consisted of radiation therapy with a total dose of 50.4 Gy after R1 resection in 2 cases and biopsy in 1 case. After a median follow-up of 32 months, 2 patients who had received VDC/paclitaxel were alive without events (with complete and partial response), 3 patients died of progressive disease. Our data confirm the aggressive behavior of angiosarcoma in children. Protocol therapy that includes multiagent chemotherapy based on paclitaxel and doxorubicin along with local control treatment makes it possible to achieve a long-term control of the disease in some patients. However, further research on molecular and genetic characteristics of angiosarcoma is required to find potential novel targets for molecular targeted therapy. Further studies investigating the effectiveness of checkpoint inhibitors in angiosarcoma are also needed.
- Open Access
- 29 November 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (23) , 16923
Complex Chromosomal Rearrangement Involving Chromosomes 10 and 11, Accompanied by Two Adjacent 11p14.1p13 and 11p13p12 Deletions, Identified in a Patient with WAGR Syndrome
Three years ago, our patient, at that time a 16-month-old boy, was discovered to have bilateral kidney lesions with a giant tumor in the right kidney. Chemotherapy and bilateral nephron-sparing surgery (NSS) for Wilms tumor with nephroblastomatosis was carried out. The patient also had eye affection, including glaucoma, eye enlargement, megalocornea, severe corneal swelling and opacity, complete aniridia, and nystagmus. The diagnosis of WAGR syndrome was suspected. De novo complex chromosomal rearrangement with balanced translocation t(10,11)(p15;p13) and a pericentric inversion inv(11)(p13q12), accompanied by two adjacent 11p14.1p13 and 11p13p12 deletions, were identified. Deletions are raised through the complex molecular mechanism of two subsequent rearrangements affecting chromosomes 11 and 10. WAGR syndrome diagnosis was clinically and molecularly confirmed, highlighting the necessity of comprehensive genetic testing in patients with congenital aniridia and/or WAGR syndrome.
- 29 November 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (23) , 16923
Open AccessComplex Chromosomal Rearrangement Involving Chromosomes 10 and 11, Accompanied by Two Adjacent 11p14.1p13 and 11p13p12 Deletions, Identified in a Patient with WAGR Syndrome
Three years ago, our patient, at that time a 16-month-old boy, was discovered to have bilateral kidney lesions with a giant tumor in the right kidney. Chemotherapy and bilateral nephron-sparing surgery (NSS) for Wilms tumor with nephroblastomatosis was carried out. The patient also had eye affection, including glaucoma, eye enlargement, megalocornea, severe corneal swelling and opacity, complete aniridia, and nystagmus. The diagnosis of WAGR syndrome was suspected. De novo complex chromosomal rearrangement with balanced translocation t(10,11)(p15;p13) and a pericentric inversion inv(11)(p13q12), accompanied by two adjacent 11p14.1p13 and 11p13p12 deletions, were identified. Deletions are raised through the complex molecular mechanism of two subsequent rearrangements affecting chromosomes 11 and 10. WAGR syndrome diagnosis was clinically and molecularly confirmed, highlighting the necessity of comprehensive genetic testing in patients with congenital aniridia and/or WAGR syndrome.
- Open Access
- 30 September 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (3) , 104-120
The efficacy of the TRK inhibitor entrectinib in patients with extracranial NTRK fusion-positive tumors
Somatic translocations involving the NTRK genes occur in 0.34–2.2% of all malignant neoplasms in children. TRK inhibitors whose efficacy has been demonstrated in prospective clinical studies expand treatment options for patients with solid tumors harboring NTRK gene rearrangements. The aim of our study was to summarize the first Russian experience with the use of the TRK inhibitor entrectinib in patients with extracranial NTRK fusion-positive solid tumors included in the compassionate use program. This study was approved by the Independent Ethics Committee and the Academic Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. The study included 8 patients who had been treated at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology and the N.N. Blokhin National Medical Research Center of Oncology. The main criteria for inclusion in the compassionate use program were a confirmed rearrangement of either NTRK1/2/3 genes in a solid tumor in patients with unresectable disease for whom no effective standard systemic therapy was available, progressive or recurrent disease during therapy prescribed according to the established diagnosis, risk group and risk stratification criteria, and the infeasibility of non-mutilating radical surgery. The median age at diagnosis was 4.3 months (range 1.2–83.6). The male to female ratio was 1:1. The primary site distribution was as follows: head and neck (n = 6; 75%), chest wall (n = 1; 12.5%), pelvis (n = 1; 12.5%). None of the patients had regional lymph node involvement or distant metastases at diagnosis. The distribution by histology (according to histopathology reports) was as follows: infantile fibrosarcoma (n = 4; 50%), undifferentiated round cell sarcoma, low-grade (n = 1; 12.5%), undifferentiated spindle cell sarcoma, high-grade (n = 1; 12.5%), NTRK-rearranged spindle cell sarcoma, low-grade (n = 1; 12.5%), spindle cell tumor associated with an NTRK rearrangement (n = 1; 12.5%). Immunohistochemistry (IHC) with a pan-Trk monoclonal antibody was performed in 7/8 (87.5%) patients. Pan-Trk IHC was positive in 4/7 (57%) patients. Rearrangements in the NTRK1 and NTRK3 genes were confirmed in all the patients. The final methods used for the detection of fusion transcripts were as follows: reverse transcription polymerase chain reaction (n = 4; 50%) and RNA-based next-generation sequencing (n = 4; 50%). NTRK1 and NTRK3 gene translocations were detected in 3/8 (37.5%) and 5/8 (62.5%) patients, respectively. The following fusion transcripts were identified: ETV6::NTRK3 (n = 4), DIP2C::NTRK3 (n = 1), TPR::NTRK1 (n = 1), TPM3::NTRK1 (n = 1), MYH10::NTRK1 (n = 1). One (12.5%) patient received entrectinib as first-line therapy, other patients (7/8, 87.5%) received entrectinib as secondor subsequent-line therapy. Three (37.5%) patients had undergone surgery before treatment with entrectinib: 2 had R2 resection, 1 had R0/R1 resection (resection margins were not evaluated). None of the patients received radiation therapy. The median duration of entrectinib therapy at the time of analysis was 11.8 months (range 2.3–20.1). Delayed surgery was performed in 2/8 patients; according to the histopathology reports, they achieved grade IV pathomorphosis. Three patients experienced adverse events during treatment with entrectinib. The median time to adverse events was 0.23 months (range 0.2–7.96). Three patients required temporary interruption in treatment to relieve symptoms, a subsequent dose reduction by one dose level was necessary when resuming therapy in two patients. The median follow-up since diagnosis was 19.5 months (range 14.9–75.0). All the patients included in our analysis were alive, three of them had no radiologic evidence of disease. Fifty percent of the patients completed targeted therapy, another 50% of the patients continued treatment with entrectinib. Complete and very good partial response was achieved in 3/8 and 2/8 patients, respectively. Partial response, minor partial response and stable disease were observed in one patient each. These results indicate high efficacy and safety of entrectinib in pediatric patients with extracranial NTRK fusion-positive solid tumors. Further studies are needed to determine the therapeutic potential of TRK inhibitors in the treatment of different solid malignant neoplasms in children and to assess long-term treatment results.
- 30 September 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (3) , 104-120
Open AccessThe efficacy of the TRK inhibitor entrectinib in patients with extracranial NTRK fusion-positive tumors
Somatic translocations involving the NTRK genes occur in 0.34–2.2% of all malignant neoplasms in children. TRK inhibitors whose efficacy has been demonstrated in prospective clinical studies expand treatment options for patients with solid tumors harboring NTRK gene rearrangements. The aim of our study was to summarize the first Russian experience with the use of the TRK inhibitor entrectinib in patients with extracranial NTRK fusion-positive solid tumors included in the compassionate use program. This study was approved by the Independent Ethics Committee and the Academic Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. The study included 8 patients who had been treated at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology and the N.N. Blokhin National Medical Research Center of Oncology. The main criteria for inclusion in the compassionate use program were a confirmed rearrangement of either NTRK1/2/3 genes in a solid tumor in patients with unresectable disease for whom no effective standard systemic therapy was available, progressive or recurrent disease during therapy prescribed according to the established diagnosis, risk group and risk stratification criteria, and the infeasibility of non-mutilating radical surgery. The median age at diagnosis was 4.3 months (range 1.2–83.6). The male to female ratio was 1:1. The primary site distribution was as follows: head and neck (n = 6; 75%), chest wall (n = 1; 12.5%), pelvis (n = 1; 12.5%). None of the patients had regional lymph node involvement or distant metastases at diagnosis. The distribution by histology (according to histopathology reports) was as follows: infantile fibrosarcoma (n = 4; 50%), undifferentiated round cell sarcoma, low-grade (n = 1; 12.5%), undifferentiated spindle cell sarcoma, high-grade (n = 1; 12.5%), NTRK-rearranged spindle cell sarcoma, low-grade (n = 1; 12.5%), spindle cell tumor associated with an NTRK rearrangement (n = 1; 12.5%). Immunohistochemistry (IHC) with a pan-Trk monoclonal antibody was performed in 7/8 (87.5%) patients. Pan-Trk IHC was positive in 4/7 (57%) patients. Rearrangements in the NTRK1 and NTRK3 genes were confirmed in all the patients. The final methods used for the detection of fusion transcripts were as follows: reverse transcription polymerase chain reaction (n = 4; 50%) and RNA-based next-generation sequencing (n = 4; 50%). NTRK1 and NTRK3 gene translocations were detected in 3/8 (37.5%) and 5/8 (62.5%) patients, respectively. The following fusion transcripts were identified: ETV6::NTRK3 (n = 4), DIP2C::NTRK3 (n = 1), TPR::NTRK1 (n = 1), TPM3::NTRK1 (n = 1), MYH10::NTRK1 (n = 1). One (12.5%) patient received entrectinib as first-line therapy, other patients (7/8, 87.5%) received entrectinib as secondor subsequent-line therapy. Three (37.5%) patients had undergone surgery before treatment with entrectinib: 2 had R2 resection, 1 had R0/R1 resection (resection margins were not evaluated). None of the patients received radiation therapy. The median duration of entrectinib therapy at the time of analysis was 11.8 months (range 2.3–20.1). Delayed surgery was performed in 2/8 patients; according to the histopathology reports, they achieved grade IV pathomorphosis. Three patients experienced adverse events during treatment with entrectinib. The median time to adverse events was 0.23 months (range 0.2–7.96). Three patients required temporary interruption in treatment to relieve symptoms, a subsequent dose reduction by one dose level was necessary when resuming therapy in two patients. The median follow-up since diagnosis was 19.5 months (range 14.9–75.0). All the patients included in our analysis were alive, three of them had no radiologic evidence of disease. Fifty percent of the patients completed targeted therapy, another 50% of the patients continued treatment with entrectinib. Complete and very good partial response was achieved in 3/8 and 2/8 patients, respectively. Partial response, minor partial response and stable disease were observed in one patient each. These results indicate high efficacy and safety of entrectinib in pediatric patients with extracranial NTRK fusion-positive solid tumors. Further studies are needed to determine the therapeutic potential of TRK inhibitors in the treatment of different solid malignant neoplasms in children and to assess long-term treatment results.